Skip to main content
PMC home page
Springer logoLink to Springer
. 2021 Jul 10;61(1):183–196. doi: 10.1007/s00394-021-02626-9

Dairy product consumption and incident prediabetes in Dutch middle-aged adults: the Hoorn Studies prospective cohort

Isabel A L Slurink 1,✉, Nicolette R den Braver 2, Femke Rutters 2, Nina Kupper 1, Tom Smeets 1, Petra J M Elders 2, Joline W J Beulens 2,3, Sabita S Soedamah-Muthu 1,4
PMCID: PMC8783852  PMID: 34245355

Abstract

Purpose

Our aim was to investigate prospective associations of consumption of total dairy and dairy types with incident prediabetes in a Dutch population-based study.

Methods

Two enrolment waves of the Hoorn Studies were harmonized, resulting in an analytic sample of 2262 participants without (pre-) diabetes at enrolment (mean age 56 ± 7.3 years; 50% male). Baseline dietary intake was assessed by validated food frequency questionnaires. Relative risks (RRs) were calculated between dairy, fermented dairy, milk, yogurt (all total/high/low fat), cream and ice cream and prediabetes. Additionally, substituting one serving/day of dairy types associated with prediabetes with alternative dairy types was analysed.

Results

During a mean 6.4 ± 0.7 years of follow-up, 810 participants (35.9%) developed prediabetes. High fat fermented dairy, cheese and high fat cheese were associated with a 17% (RR 0.83, 95% CI 0.69–0.99, ptrend = 0.04), 14% (RR 0.86, 95% CI 0.73–1.02, ptrend = 0.04) and 21% (RR 0.79, 95% CI 0.66–0.94, ptrend = 0.01) lower risk of incident prediabetes, respectively, in top compared to bottom quartiles, after adjustment for confounders. High fat cheese consumption was continuously associated with lower prediabetes risk (RRservings/day 0.94, 95% CI 0.88–1.00, p = 0.04). Total dairy and other dairy types were not associated with prediabetes risk in adjusted models, irrespective of fat content (RR ~ 1). Replacing high fat cheese with alternative dairy types was not associated with prediabetes risk.

Conclusion

The highest intake of high fat fermented dairy, cheese and high fat cheese were associated with a lower risk of prediabetes, whereas other dairy types were not associated. Cheese seems to be inversely associated with type 2 diabetes risk, despite high levels of saturated fatty acids and sodium.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00394-021-02626-9.

Keywords: Dairy, Impaired glucose metabolism, Prediabetes, Prospective cohort

Introduction

Prediabetes is a condition characterized by blood glucose levels that are above the normal range, but still fall below the diagnostic threshold for type 2 diabetes [1].The prevalence of prediabetes is rapidly rising worldwide from 374 million in 2019 to an expected 548 million in 2045 [2]. People with prediabetes are at increased risk of developing type 2 diabetes (T2D) and cardiovascular diseases (CVD) [3, 4], but may reverse to normoglycaemia with lifestyle adaptation [5]. This emphasizes the need to identify modifiable risk factors that could prevent or reverse this condition. Suboptimal diet is causally linked to incidence of prediabetes and T2D, and majority of cases can be prevented by dietary modification [6, 7].

Dairy products are widely consumed and may provide considerable quantities of beneficial nutrients for metabolic health, including protein, minerals (calcium, magnesium, potassium) and vitamins (A, D, B2, B12), but also contain saturated fatty acids (SFAs) and sodium. A recent summary of meta-analyses reported dose–response relations of low fat dairy (RRs ranging from 0.88–0.98), yogurt (0.78–0.94) and cheese (0.80–1.00) with T2D, inconsistent results for milk (RRs 0.83–1.27), with considerable heterogeneity present between studies [8]. One possible explanation for heterogeneity, proposed by Hruby et al., could be differences in participant’s baseline glycaemic status [9], and the precise moment along the physiological progress of T2D at which specific dairy products modify risk is largely unknown. Therefore, studies aiming to elucidate associations between dairy and early-risk stages are warranted.

Only one prospective cohort study investigated the associations of dairy products with incident prediabetes, based on fasting plasma glucose (FPG) [9]. In the US FHS Offspring Cohort (n = 1867, 12-year follow-up), highest consumption of total, low fat and high fat dairy was associated with 39%, 32% and 25% lower prediabetes incidence, respectively, compared to lowest consumption, with nonlinear protective associations for milk and yogurt. In the French DESIR study (9-year follow-up), prediabetes and T2D were combined as one outcome, inhibiting interpretation of associations with prediabetes alone. The DESIR study observed an association between higher total dairy (except cheese) intake with lower hyperglycaemia incidence [10]. Furthermore, two studies investigating continuous outcomes of glucose metabolism showed no associations of any dairy types [11, 12], except for an association of higher fermented dairy with lower FPG and HbA1c in the Danish Inter99 study [11]. Evidence from cross-sectional studies indicated that mainly higher fermented and skimmed dairy intake were associated with lower prediabetes risk [13–15], with one study also reporting associations for higher non-fermented and high fat dairy intake and higher prediabetes risk [14]. Thus, although there are some indications for beneficial associations of dairy consumption on prediabetes risk, associations are highly heterogeneous, partly underlined by different definitions of prediabetes outcomes and large variations in dairy consumption habits, advocating the need for country and region-specific prospective data.

Therefore, this study aimed to investigate prospective associations between consumption of total dairy and dairy types with incident prediabetes.

Methods

Study population

This study used data of the Hoorn Studies, a prospective population-based cohort study with the first enrolment wave in 1989–1992 (Hoorn Study 1, HS1) and a second wave in 2006–2007 (HS2). The aim was to study prevalence and risk factors for disturbances in glucose metabolism and T2D. Both enrolment waves were similar in design, population characteristics and questionnaires [16], and could, therefore, be harmonized to increase sample size and study power. Furthermore, this harmonization resulted in increased variation in dairy product intake and inclusion of more up-to-date information. People from the general population were recruited, aged 50–75 years in the HS1 and 40–65 years in the HS2 at time of inclusion. Follow-up measurements were performed between the years 1996–1998 in the HS1 and 2013–2015 in the HS2. Visits took place at the Diabetes Care Center in the city of Hoorn, the Netherlands. Written informed consent was obtained from all participants. The study was approved by the Ethics Committee of the Amsterdam University Medical Centers, location VUMC.

From participants with follow-up data available (n = 3245), we excluded participants with prediabetes (n = 557) or T2D at baseline (n = 229) or follow-up (n = 528) (Supplemental Fig. 1). Exclusion of prediabetes was based on FPG between 6.1–7.0 mmol/L, 2 h plasma glucose (2hPG) between 7.8 and 11.0 mmol/L and/or HbA1c levels between 6.0 and 6.5% [1, 17]. Exclusion of T2D was based on diagnosis by a general practitioner, diabetes medication user and/or an FPG ≥ 7.0 mmol/L, 2hPG ≥ 11.1 mmol/L, or HbA1c ≥ 6.5%. Other exclusion criteria were self-reported history of T2D prior to baseline (n = 59), extreme energy intake (top and bottom 0.5%) (n = 34) or missing information on dairy intake (n = 42), and/or missing data on prediabetes at follow-up (n = 9). After exclusion, the analytic sample consisted of 2262 participants.

Assessment of dairy consumption

Baseline dietary intake was assessed with a 92-item food frequency questionnaire (FFQ) in the HS1 and a 104-item FFQ in the HS2. The HS1 FFQ was validated against a dietary history in 74 males and females, and was valid for ranking individuals according to energy intake (r = 0.72), and main nutrients in dairy products; animal protein (r = 0.82), SFAs (r = 0.73) and calcium (r = 0.75) [18]. The HS2 FFQ was validated against actual energy intake in controlled feeding trials for energy intake (r = 0.82) [19] and validated against three 24-h recalls for animal protein (r = 0.49), SFA (r = 0.44) and calcium (r = 0.56) [20].

Participants were asked to report their usual frequency of consumption, serving size and preparation in the past year. Seasonal variations in milk consumption were assessed with separate questions for winter and summer intakes. Participants completed the questionnaire at home, and checked for completeness by a trained dietician. Intake (gram/day) per FFQ item was calculated using the Dutch food composition table (NEVO) 1989/1990 for HS1 and the NEVO 2006 for HS2. FFQ items were combined and categorized as total dairy, fermented dairy, and by subtypes milk (all types and regular milk), yogurt, cheese, cream and ice cream (Table 1). Each dairy category was further divided into low fat (liquid products, ≤ 2%; cheese ≤ 20%) and high fat (liquid products, > 2%; cheese > 20%). Intakes were converted to servings/day according to Dutch standard serving sizes: milk, 200 mL; yogurt, 150 mL; cheese, 20 g; cream, 3 g; ice cream, 100 g (https://portie-online.rivm.nl/). In the total dairy category, a serving of liquid dairy products was defined as 200 mL and a serving of cheese as 20 g. Because two different FFQs were used, dietary intakes of food groups and dairy types stratified by enrolment wave are reported in Supplementary Table 1.

Table 1.

Individual dairy products included and grouping for the present analysis of the Hoorn Studies

Dairy product Included dairy types
Total dairy All dairy products
 High fat dairy All high fat dairy products
 Low fat dairy All low fat dairy products
Fermented dairy
 High fat1 Full fat yogurt, full fat fruit yogurt, full fat curd, high fat cheese, full fat luxury cheese
 Low fat2 Semi-skimmed yogurt, skimmed yogurt, skimmed fruit yogurt, semi-skimmed curd, skimmed curd, semi-skimmed fruit curd, skimmed fruit curd, low fat cheese, low fat luxury cheese
Milk, all types
 High fat Full fat milk, full fat chocolate milk, milk powder, full fat milk added to the coffee, drinking yogurt3, fruit flavoured milk3
 Low fat Semi-skimmed milk, skimmed milk, buttermilk, semi-skimmed chocolate milk, skimmed chocolate milk, semi-skimmed milk added to the coffee, skimmed milk added to the coffee, semi-skimmed fruit milk
Regular milk
 High fat Full fat milk
 Low fat Semi-skimmed milk, skimmed milk, buttermilk
Yogurt
 High fat1 Full fat yogurt, full fat fruit yogurt
 Low fat4 Semi-skimmed yogurt, skimmed yogurt, skimmed fruit yogurt
Cheese
 High fat HS1: regular cheese, cheese cubes; HS2: 40 + cheese (e.g. Edam), 48 + cheese (e.g. Gouda, cheddar, cheese spread, goat cheese), full fat luxury cheese (e.g. cream brie, cream cheese, mon chou), cheese cubes, grated cheese, feta, cheese fondue
 Low fat HS1: skimmed cheese; HS2: 20 + and 30 + cheese (e.g. cheese spread, cottage cheese), low fat luxury cheese (e.g. brie, goat cheese)
Cream (high fat) Whipped cream, coffee cream, semi-skimmed coffee cream, sour cream, crème fraiche, cooking cream
Ice cream (high fat) Ice cream
Open in a new tab

HS1 Hoorn Studies 1 (first enrolment wave), HS2 Hoorn Studies 2 (second enrolment wave)

1Includes oatmeal porridge, rice porridge and full fat custard in HS2

2Includes buttermilk in HS1, buttermilk porridge and skimmed custard in HS2

3Only assessed in HS2

4Includes semi-skimmed curd, skimmed curd, semi-skimmed fruit curd, skimmed fruit curd, buttermilk porridge and skimmed custard in HS2

Outcome assessment

At all study visits, bloods samples were drawn to determine FPG, 2hPG levels after a 75-g oral glucose tolerance test (OGTT) and HbA1c levels, except at the HS2 follow-up visit, where no OGTT was conducted and HbA1c was measured in fasting capillary blood samples obtained using a blood spot card. FPG and 2hPG levels were determined using the glucose dehydrogenase method (Merck, Darmstadt, Germany). In the HS1, HbA1c was determined by ion-exchange high-performance liquid chromatography with a Modular Diabetes Monitoring System (Bio-Rad, Veenendaal, The Netherlands). In the HS2 at baseline, HbA1c levels were assessed using standardized reverse-phase cation-exchange chromatography (HA 8160 analyzer; Menarini, Florence, Italy). In the HS2 at follow-up, HbA1c levels were derived from blood spot cards, using thermo immunoturbidimetry according to a validated protocol [21]. Prediabetes at follow-up was defined according to the diagnostic criteria of the World Health Organization of 2006 [1], complemented with the HbA1c cut-offs values proposed by the 2009 international expert committee for prediabetes [17], with FPG between 6.1–7.0 mmol/L, 2hPG between 7.8–11.0 mmol/L and/or HbA1c levels between 6.0–6.5%.

Other variables

The self-administered baseline questionnaire for both enrolment waves included questions on socio-demographic, lifestyle and clinical factors. Responses were verified in a personal interview. Smoking status was categorized as current, former, or never. Highest educational level was obtained in eight levels, which were subsequently categorized to low (no education or primary school), middle (secondary education) and high (tertiary education). Moderate physical activity in hours/week was assessed using the SQUASH questionnaire, for which the Spearman correlation for overall reproducibility was 0.58 in 50 participants compared to an activity monitor [22]. The activities included sports, bicycling, gardening, walking, doing chores and housekeeping. Alcohol intake was categorized as non-drinker, ≤ 10, 10–30 and ≥ 30 g/day. Family history of diabetes was defined as having at least a grandparent, parent, sibling or child with diabetes.

Physical measurements were performed at baseline. BMI was calculated as weight divided by height squared (kg/m2), and categorized as < 25 kg/m2, 25–30 kg/m2 and ≥ 30 kg/m2. Blood pressure was measured on the right arm with a random-zero sphygmomanometer (Hawksley–Gelman Ltd, Lancing, United Kingdom) while participants were sitting. Plasma levels of total cholesterol, triglycerides, high-density lipoprotein (HDL) were measured in fasting blood samples by enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany) and low-density lipoprotein (LDL) was calculated using the Friedewald formula (except for participants with triglycerides > 4.55 mmol/L) [23].

Statistical analysis

Statistical analyses were performed using R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria). Baseline characteristics are displayed as means ± SD, medians (IQR) or percentages for the total study population and in quartiles of total dairy intake. Missing values in confounding variables (for 6% of participants, highest 2% for physical activity) were imputed using multiple imputation (n = 10).

Poisson regression with robust variance was used to examine associations between dairy product intakes and prediabetes, because of the high incidence of prediabetes (35.9%), in which case the odds ratio overestimates the strength of the association [24]. RRs with 95% CIs were calculated for quartiles of dairy intake (reference lowest) and on a continuous scale (servings/day). Dairy products for which many participants reported no intake were divided in a non-consumer category (reference) and consumers in tertiles. Linear trend across intake range categories were assessed by including median values of each category as a continuous variable in the model. Linearity was assumed in all models, as no indications for non-linearity presented assessed by adding a quadratic term to model 3. Regression coefficients for each of the imputed datasets were pooled.

Confounder models were constructed based on literature [25] and on distributions of baseline characteristics across quartiles. Model 1 included age, sex, follow-up duration and enrolment wave. Model 2 additionally adjusted for energy intake, education, smoking, physical activity, alcohol consumption and family history of diabetes. Model 3 additionally adjusted for food groups associated with T2D including intakes of fruit, vegetables, tea, coffee, grains (whole and refined), meat (processed and red) and sugar-sweetened beverages [26, 27]. BMI, blood pressure (systolic and diastolic) and LDL cholesterol were added separately in model 4 because of their potential mediating or otherwise confounding effect. We checked for effect modification by enrolment wave by including an interaction term in model 3 and stratified associations by enrolment wave to assess if associations differed for each wave of the Hoorn Studies. Furthermore, effect modification by age, sex and BMI was examined, and associations were stratified in case of significance.

We provided a supplementary baseline table stratified by the dairy types that were significantly associated with prediabetes in the main analyses, to examine confounding of associations by healthy lifestyle. Furthermore, we examined substituting one serving/day of significant dairy types with alternative dairy types in model 3. Models included a total dairy intake variable (servings/day), all individual dairy types (servings/day) except for the dairy type to be substituted, and energy intake. The estimated RR for each alternative dairy type can be interpreted as the RR for substitution of a daily serving of the alternative dairy type for a daily serving of the excluded dairy type [28].

A series of sensitivity analyses were conducted using model 3. First, the independence of the associations of specific dairy types was tested by mutually adjusting for intake of other dairy types. Second, we repeated the analysis excluding participants with self-reported CVD (n = 261). Third, we repeated the analysis in ‘normal energy reporters’ only, identified using the Goldberg method [29]. For this method, the basal metabolic rate (BMR) was calculated for each participant using Schofield equations specifically for age and sex categories based on weight [30]. Following, the ratio of energy intake (EI) and BMR was calculated. Using the Goldberg cut-offs described by Black et al., participants with EI:BMR < 1.08 were classified as under-reporters, participants with 1.08 ≤ EI:BMR ≤ 2.22 were classified as ‘normal reporters’ and those with EI:BMR > 2.22 were defined as ‘over-reporters’ [29]. Lastly, to address possible misclassification in prediabetes defined at baseline, we repeated analyses including participants with prediabetes at baseline (n = 557, final sample n = 2661).

Results

Participant characteristics

The mean age of the study population was 55.9 ± 7.3 years, 50% were male and 22% were current smokers (Table 2, by enrolment wave Supplemental Table 1). The mean BMI was 25.7 ± 3.4 kg/m2 and 10% of participants were obese (BMI ≥ 30 kg/m2). The mean dairy intake was 3.0 ± 1.7 servings/day (357 ± 237 g/day) (Fig. 1). Participants in the top (3.9–15.4 servings/day) compared to the bottom quartile (0–1.8 servings/day) of dairy intake were more often male (54% vs 43%), with low education (16% vs 8%), more physically active (median (IQR): 9.0 (5.1–13.7) vs 6.5 (3.5–10.5) hours/week) and had higher LDL cholesterol levels (4.2 ± 1.1 vs 3.5 ± 1.0 mmol/L). With increasing dairy intake over the quartiles, energy, calcium, fruit and processed meat intakes were higher and vegetable and alcohol intakes were lower. Participants with complete follow-up data (n = 3245) were similar to participants lost-to-follow-up (n = 2046) with regard to age (56.9 ± 7.6 vs 58.0 ± 9.0 years), sex (51% vs 49% male), physical activity (7.5 IQR 4.0–12.3 vs 7.0 IQR 3.5–12.7 h/week), BMI (26.3 ± 3.6 vs 26.6 ± 4.1 kg/m2) and fasting glucose (5.6 ± 1.0 vs 5.8 ± 1.6 mmol/L) (Supplemental Table 2). Participants lost-to-follow-up were slightly more often lower educated (22% vs 15%), current smoker (31% vs 23%) and had a lower alcohol intake (median 5.0 IQR 0.0–15.3 vs 7.2 IQR 2.0–17.2).

Table 2.

Baseline characteristics and dietary intakes of participants of the Hoorn Studies according to quartiles of total dairy intake (n = 2262)

N missing Total population Q1 Q2 Q3 Q4
(n = 2262) (n = 562) (n = 573) (n = 561) (n = 566)
Dairy intake (servings/day)
 Range 0–1.8 1.8–2.7 2.7–3.9 3.9–15.4
 Median 2.7 1.3 2.3 3.3 5.0
Follow-up time (year) 6.4 ± 0.7 6.6 ± 0.7 6.4 ± 0.7 6.4 ± 0.7 6.2 ± 0.6
Sex (men) 50% (1132) 43% (243) 52% (296) 52% (289) 54% (304)
Age (year) 55.9 ± 7.3 54.1 ± 7.1 55.6 ± 7.3 56.6 ± 7.5 57.3 ± 7.1
Education level 22
 Low 13% (299) 8% (46) 15% (84) 14% (79) 16% (90)
 Middle 58% (1310) 60% (336) 54% (309) 57% (317) 61% (348)
 High 28% (631) 31% (172) 30% (174) 28% (159) 22% (126)
Smoking 10
 Current 22% (493) 20% (115) 23% (131) 22% (124) 22% (123)
 Previous (> 2 months ago) 38% (851) 40% (226) 37% (211) 37% (208) 36% (206)
 Never 40% (908) 38% (216) 40% (228) 41% (228) 42% (236)
 Cigarette years 663 210 (9–480) 290 (100–560) 220 (30–470) 180 (0–450) 160 (0–460)
Alcohol intake 1
 0 g/day 18% (401) 15% (87) 18% (103) 17% (97) 20% (114)
 ≤ 10 g/day 42% (959) 42% (237) 43% (246) 40% (226) 44% (250)
 10–30 g/day 30% (678) 30% (170) 31% (178) 32% (179) 27% (151)
 ≥ 30 g/day 10% (223) 12% (68) 8% (45) 11% (59) 9% (51)
Family history diabetes mellitus 11 24% (553) 25% (141) 27% (152) 21% (119) 25% (141)
Physical activity, moderate intensity, hours/week 47 7.5 (4.2–12.0) 6.5 (3.5–10.5) 7.0 (3.8–12.0) 7.8 (4.5–12.6) 9.0 (5.1–13.7)
BMI (kg/m2) 4 25.7 ± 3.4 25.9 ± 3.5 25.5 ± 3.2 25.5 ± 3.3 26.1 ± 3.4
Fasting glucose (mmol/L) 7 5.3 ± 0.4 5.3 ± 0.4 5.3 ± 0.4 5.2 ± 0.4 5.2 ± 0.4
Systolic blood pressure (mmHg) 2 130 ± 17 130 ± 16 130 ± 18 130 ± 17 130 ± 18
Diastolic blood pressure (mmHg) 5 78 ± 11 78 ± 11 78 ± 11 79 ± 10 80 ± 10
Antihypertensive medication use 13% (304) 16% (92) 12% (70) 13% (73) 12% (69)
LDL cholesterol (mmol/L) 6 3.8 ± 1.1 3.5 ± 1.0 3.8 ± 1.1 3.9 ± 1.1 4.2 ± 1.1
Lipid lowering medication 5% (108) 9% (50) 4% (22) 3% (18) 3% (18)
Dietary intake
 Energy intake (kcal/day) 2100 ± 600 1900 ± 540 2100 ± 530 2200 ± 570 2400 ± 620
 DHD15-index score 70 ± 14 66 ± 14 71 ± 14 72 ± 14 70 ± 13
 Fruit (g/day) 200 ± 140 160 ± 130 190 ± 130 200 ± 130 240 ± 150
 Vegetables (g/day) 150 ± 85 170 ± 91 150 ± 83 150 ± 86 140 ± 75
 Grain (g/day) 5 200 ± 95 200 ± 95 200 ± 92 200 ± 96 200 ± 96
 Red meat (g/day) 1 34 ± 23 37 ± 23 35 ± 22 33 ± 23 31 ± 23
 Processed meat (g/day) 46 ± 33 37 ± 30 44 ± 32 47 ± 33 54 ± 35
 Lean fish (g/day) 11 ± 13 11 ± 12 11 ± 13 11 ± 12 12 ± 14
 Fatty fish (g/day) 5.0 ± 8.4 4.9 ± 7.2 5.4 ± 10.6 4.7 ± 7.4 4.9 ± 8.1
 Coffee (g/day) 500 ± 270 450 ± 290 490 ± 270 520 ± 250 540 ± 270
 Tea (g/day) 3 280 ± 260 270 ± 290 280 ± 250 290 ± 250 300 ± 260
 Fruit juice (g/day) 3 60 ± 95 69 ± 110 60 ± 89 54 ± 83 55 ± 98
 Sugar-sweetened beverages (g/day) 110 ± 140 130 ± 160 110 ± 140 100 ± 130 110 ± 150
 Saturated fat (en%) 14.6 ± 3.7 12.6 ± 3.3 14.2 ± 3.3 15.2 ± 3.4 16.6 ± 3.5
 Protein (en%) 14.5 ± 2.4 13.8 ± 2.3 14.3 ± 2.3 14.6 ± 2.2 15.4 ± 2.5
 Calcium (g/day) 1000 ± 370 650 ± 180 880 ± 160 1100 ± 160 1500 ± 300
Open in a new tab

Variables are displayed as means ± SD for normally distributed continuous variables, medians (IQR) for non-normally distributed continuous variables or % (n) for categorical variables

BMI body mass index, DHD15-index Dutch Healthy Diet 2015 index score [56], HS1 Hoorn Studies 1 (first enrolment wave), LDL low-density lipoprotein

Fig. 1.

Fig. 1

Open in a new tab

Mean dairy consumption in the Hoorn Studies (n = 2262)

Dairy intake and incident prediabetes

During a mean follow-up duration of 6.4 ± 0.7 years, 811 out of 2262 participants developed prediabetes (35.9%). High fat fermented dairy intake was significantly associated with lower prediabetes risk in model 3 (RRQ4vsQ1: 0.83, 95% CI 0.69–0.99, ptrend = 0.04) (Table 3). High fat fermented dairy intake mainly consisted of cheese intake (63%), which was marginally significantly associated with lower risk of prediabetes (RR top vs bottom quartile: 0.86, 95% CI 0.73–1.02, ptrend = 0.04). Specifically, higher intake of high fat cheese (52% of high fat fermented dairy, 83% of total cheese intake) was significantly associated with lower prediabetes risk (RRQ4vsQ1: 0.79, 95% CI 0.66–0.94, ptrend = 0.006). High fat cheese was the only dairy type continuously associated with prediabetes (RRservings/day: 0.94, 95% CI 0.88–1.00, p = 0.04). Total dairy, fermented dairy, milk, regular milk, yogurt, cream and ice cream intake both in quartiles and continuously were not associated with risk of prediabetes in multivariate adjusted models (RR ~ 1). Further adjustment for BMI, LDL cholesterol and blood pressure in model 4 did not change the associations.

Table 3.

Risk ratios (95% confidence interval) for the association between dairy intake and incidence of prediabetes, the Hoorn Studies (n = 2262)

Continuous1 Intake range categories ptrend
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Total dairy Q1 Q2 Q3 Q4
 n/N 216/562 216/573 183/561 196/566
 Median 1.3 2.3 3.3 5.0
 Model 1 0.98 (0.95–1.02) 1 1.00 (0.86–1.16) 0.88 (0.75–1.03) 0.96 (0.82–1.14) 0.49
 Model 2 0.98 (0.94–1.02) 1 1.00 (0.86–1.17) 0.87 (0.73–1.02) 0.95 (0.80–1.14) 0.41
 Model 3 0.98 (0.94–1.02) 1 1.00 (0.86–1.16) 0.87 (0.74–1.03) 0.95 (0.79–1.13) 0.38
 Model 4 0.97 (0.93–1.01) 1 1.01 (0.87–1.18) 0.88 (0.74–1.04) 0.93 (0.78–1.12) 0.30
High fat dairy Q1 Q2 Q3 Q4
 n/N 217/565 216/567 198/563 180/567
 Median 0.1 0.9 1.7 3.1
 Model 1 0.97 (0.92–1.01) 1 1.01 (0.87–1.18) 0.95 (0.81–1.12) 0.88 (0.74–1.05) 0.11
 Model 2 0.95 (0.91–1.00) 1 1.00 (0.86–1.16) 0.92 (0.78–1.08) 0.84 (0.70–1.01) 0.04
 Model 3 0.96 (0.91–1.01) 1 1.01 (0.87–1.17) 0.94 (0.79–1.11) 0.85 (0.71–1.03) 0.06
 Model 4 0.95 (0.91–1.00) 1 1.00 (0.86–1.16) 0.94 (0.80–1.11) 0.85 (0.71–1.03) 0.07
Low fat dairy Q1 Q2 Q3 Q4
 n/N 203/566 210/561 208/576 190/559
 Median 0.2 0.9 1.6 2.8
 Model 1 1.01 (0.96–1.06) 1 1.03 (0.89–1.21) 1.00 (0.86–1.16) 0.95 (0.81–1.12) 0.46
 Model 2 1.01 (0.97–1.06) 1 1.06 (0.91–1.24) 1.02 (0.87–1.19) 0.98 (0.83–1.15) 0.67
 Model 3 1.01 (0.96–1.06) 1 1.06 (0.91–1.23) 1.01 (0.87–1.18) 0.96 (0.82–1.13) 0.48
 Model 4 1.00 (0.96–1.05) 1 1.06 (0.91–1.23) 1.00 (0.86–1.17) 0.94 (0.80–1.11) 0.35
Total fermented dairy Q1 Q2 Q3 Q4
 n/N 224/570 188/562 205/566 194/564
 Median 0.7 1.5 2.4 3.7
 Model 1 0.98 (0.94–1.02) 1 0.86 (0.73–1.00) 0.94 (0.81–1.10) 0.94 (0.80–1.10) 0.73
 Model 2 0.98 (0.94–1.02) 1 0.87 (0.75–1.02) 0.95 (0.81–1.10) 0.94 (0.79–1.11) 0.68
 Model 3 0.98 (0.94–1.03) 1 0.88 (0.75–1.03) 0.95 (0.81–1.11) 0.95 (0.80–1.13) 0.81
 Model 4 0.98 (0.93–1.02) 1 0.89 (0.76–1.04) 0.95 (0.81–1.11) 0.94 (0.79–1.11) 0.65
High fat fermented dairy Q1 Q2 Q3 Q4
 n/N 226/571 188/513 219/613 178/565
 Median 0.0 0.7 1.4 2.6
 Model 1 0.96 (0.91–1.01) 1 0.94 (0.81–1.09) 0.93 (0.80–1.09) 0.85 (0.72–1.00) 0.05
 Model 2 0.94 (0.89–1.00) 1 0.93 (0.79–1.08) 0.91 (0.78–1.07) 0.81 (0.68–0.97) 0.02
 Model 3 0.95 (0.90–1.01) 1 0.94 (0.80–1.09) 0.93 (0.79–1.08) 0.83 (0.69–0.99) 0.04
 Model 4 0.95 (0.89–1.00) 1 0.94 (0.80–1.10) 0.93 (0.80–1.09) 0.82 (0.68–0.98) 0.03
Low fat fermented dairy Q1 Q2 Q3 Q4
 n/N 207/565 204/566 203/557 197/574
 Median 0.0 0.4 0.9 1.9
 Model 1 1.02 (0.97–1.09) 1 0.97 (0.83–1.13) 0.97 (0.83–1.13) 0.95 (0.81–1.11) 0.55
 Model 2 1.03 (0.97–1.10) 1 0.99 (0.84–1.15) 0.99 (0.84–1.15) 0.97 (0.83–1.14) 0.73
 Model 3 1.03 (0.97–1.10) 1 0.99 (0.85–1.16) 0.98 (0.84–1.15) 0.96 (0.82–1.13) 0.64
 Model 4 1.03 (0.97–1.09) 1 0.99 (0.85–1.16) 0.99 (0.84–1.15) 0.96 (0.82–1.12) 0.57
Total milk, all types Q1 Q2 Q3 Q4
 n/N 197/562 206/570 222/566 186/564
 Median 0.1 0.6 1.2 2.1
 Model 1 1.01 (0.95–1.07) 1 1.04 (0.89–1.21) 1.15 (0.99–1.34) 1.00 (0.85–1.19) 0.83
 Model 2 1.01 (0.95–1.08) 1 1.05 (0.90–1.22) 1.16 (1.00–1.35) 1.01 (0.85–1.20) 0.78
 Model 3 1.00 (0.94–1.06) 1 1.02 (0.87–1.19) 1.13 (0.97–1.31) 0.96 (0.81–1.15) 0.79
 Model 4 0.99 (0.94–1.06) 1 1.02 (0.88–1.19) 1.14 (0.98–1.32) 0.96 (0.81–1.14) 0.81
High fat milk, all types Zero T1 T2 T3
 n/N 497/1,339 97/307 82/248 135/368
 Median 0.0 0.0 0.2 0.5
 Model 1 1.05 (0.93–1.18) 1 0.89 (0.74–1.06) 0.99 (0.80–1.22) 1.08 (0.91–1.28) 0.27
 Model 2 1.03 (0.92–1.16) 1 0.90 (0.76–1.08) 1.00 (0.81–1.23) 1.06 (0.89–1.25) 0.43
 Model 3 1.01 (0.89–1.14) 1 0.91 (0.76–1.09) 1.01 (0.82–1.24) 1.04 (0.87–1.24) 0.55
 Model 4 1.02 (0.91–1.15) 1 0.91 (0.76–1.09) 1.01 (0.82–1.24) 1.06 (0.89–1.26) 0.42
Low fat milk, all types Q1 Q2 Q3 Q4
 n/N 203/569 185/520 198/499 225/674
 Median 0.0 0.4 0.8 1.7
 Model 1 1.00 (0.94–1.07) 1 1.01 (0.86–1.18) 1.06 (0.91–1.22) 1.00 (0.84–1.18) 0.96
 Model 2 1.01 (0.94–1.07) 1 1.03 (0.88–1.21) 1.07 (0.93–1.24) 1.02 (0.86–1.21) 0.79
 Model 3 0.99 (0.93–1.06) 1 1.01 (0.86–1.19) 1.04 (0.90–1.21) 0.98 (0.83–1.17) 0.88
 Model 4 0.99 (0.93–1.05) 1 1.01 (0.86–1.18) 1.03 (0.89–1.20) 0.98 (0.82–1.15) 0.80
Total regular milk Q1 Q2 Q3 Q4
 n/N 183/534 187/521 290/755 151/452
 Median 0.0 0.3 1.0 2.1
 Model 1 1.02 (0.96–1.08) 1 1.08 (0.92–1.28) 1.14 (0.98–1.32) 1.07 (0.89–1.29) 0.41
 Model 2 1.02 (0.96–1.09) 1 1.09 (0.93–1.29) 1.15 (0.99–1.33) 1.07 (0.89–1.30) 0.42
 Model 3 1.00 (0.94–1.07) 1 1.07 (0.91–1.26) 1.11 (0.95–1.28) 1.02 (0.85–1.24) 0.79
 Model 4 1.00 (0.94–1.07) 1 1.07 (0.91–1.25) 1.11 (0.96–1.29) 1.01 (0.84–1.23) 0.83
High fat regular milk Zero T1 T2 T3
 n/N 711/1,989 30/91 34/82 36/100
 Median 0.0 0.2 0.7 1.8
 Model 1 1.04 (0.92–1.17) 1 0.98 (0.72–1.32) 1.19 (0.91–1.55) 1.07 (0.82–1.41) 0.41
 Model 2 1.02 (0.90–1.16) 1 0.95 (0.70–1.28) 1.17 (0.90–1.53) 1.04 (0.79–1.37) 0.56
 Model 3 1.00 (0.88–1.13) 1 0.94 (0.69–1.27) 1.18 (0.90–1.54) 0.99 (0.75–1.31) 0.81
 Model 4 1.01 (0.89–1.15) 1 0.94 (0.70–1.27) 1.19 (0.90–1.57) 1.03 (0.78–1.36) 0.61
Low fat regular milk Q1 Q2 Q3 Q4
 n/N 212/586 170/512 236/598 193/566
 Median 0.0 0.3 0.7 1.9
 Model 1 1.01 (0.95–1.08) 1 0.94 (0.80–1.11) 1.12 (0.97–1.30) 0.99 (0.85–1.16) 0.87
 Model 2 1.02 (0.96–1.09) 1 0.95 (0.80–1.12) 1.13 (0.98–1.31) 1.00 (0.85–1.17) 0.81
 Model 3 1.01 (0.94–1.07) 1 0.93 (0.79–1.09) 1.10 (0.95–1.28) 0.97 (0.82–1.13) 0.87
 Model 4 1.00 (0.94–1.07) 1 0.91 (0.78–1.07) 1.10 (0.95–1.27) 0.95 (0.81–1.12) 0.79
Total yogurt Q1 Q2 Q3 Q4
 n/N 201/564 196/538 205/583 209/577
 Median 0.0 0.4 0.6 1.0
 Model 1 1.02 (0.91–1.14) 1 1.00 (0.86–1.18) 0.99 (0.85–1.15) 1.01 (0.86–1.18) 0.98
 Model 2 1.05 (0.93–1.17) 1 1.03 (0.88–1.21) 1.01 (0.86–1.18) 1.04 (0.89–1.22) 0.69
 Model 3 1.04 (0.93–1.17) 1 1.05 (0.89–1.23) 1.02 (0.87–1.20) 1.04 (0.88–1.21) 0.73
 Model 4 1.06 (0.94–1.18) 1 1.04 (0.89–1.22) 1.03 (0.88–1.21) 1.05 (0.90–1.23) 0.56
High fat yogurt Zero T1 T2 T3
 n/N 550/1,575 86/229 88/219 87/239
 Median 0.0 0.1 0.3 0.8
 Model 1 1.07 (0.91–1.27) 1 1.08 (0.90–1.29) 1.14 (0.95–1.36) 1.08 (0.90–1.29) 0.25
 Model 2 1.08 (0.91–1.29) 1 1.09 (0.91–1.31) 1.16 (0.97–1.39) 1.08 (0.90–1.30) 0.24
 Model 3 1.09 (0.92–1.29) 1 1.10 (0.92–1.32) 1.19 (0.99–1.43) 1.09 (0.91–1.32) 0.19
 Model 4 1.12 (0.94–1.34) 1 1.08 (0.90–1.29) 1.20 (1.01–1.44) 1.11 (0.92–1.34) 0.13
Low fat yogurt Zero T1 T2 T3
 n/N 256/724 223/604 152/416 180/518
 Median 0.0 0.2 0.6 0.9
 Model 1 0.99 (0.88–1.12) 1 1.01 (0.87–1.18) 1.00 (0.85–1.18) 0.97 (0.84–1.13) 0.70
 Model 2 1.01 (0.90–1.15) 1 1.04 (0.89–1.21) 1.02 (0.86–1.20) 1.00 (0.86–1.17) 0.94
 Model 3 1.01 (0.89–1.14) 1 1.04 (0.90–1.21) 1.03 (0.87–1.21) 0.99 (0.85–1.16) 0.82
 Model 4 1.01 (0.89–1.14) 1 1.02 (0.88–1.19) 1.02 (0.87–1.20) 0.99 (0.85–1.15) 0.89
Total cheese Q1 Q2 Q3 Q4
 n/N 215/563 216/561 202/581 178/557
 Median 0.3 0.9 1.5 2.6
 Model 1 0.96 (0.91–1.01) 1 1.01 (0.87–1.17) 0.91 (0.78–1.07) 0.87 (0.74–1.02) 0.04
 Model 2 0.94 (0.89–1.00) 1 1.01 (0.87–1.17) 0.90 (0.77–1.04) 0.84 (0.71–0.99) 0.02
 Model 3 0.95 (0.90–1.01) 1 1.02 (0.88–1.19) 0.90 (0.77–1.05) 0.86 (0.73–1.02) 0.04
 Model 4 0.94 (0.89–1.00) 1 1.02 (0.88–1.18) 0.89 (0.76–1.03) 0.84 (0.71–1.00) 0.02
High fat cheese Q1 Q2 Q3 Q4
 n/N 223/558 225/600 188/532 175/572
 Median 0.0 0.6 1.2 2.3
 Model 1 0.94 (0.89–1.00) 1 0.96 (0.83–1.11) 0.92 (0.79–1.08) 0.81 (0.69–0.95) 0.009
 Model 2 0.93 (0.88–0.99) 1 0.94 (0.82–1.09) 0.90 (0.77–1.06) 0.77 (0.65–0.92) 0.002
 Model 3 0.94 (0.88–1.00) 1 0.95 (0.82–1.10) 0.91 (0.77–1.07) 0.79 (0.66–0.94) 0.006
 Model 4 0.93 (0.88–0.99) 1 0.95 (0.82–1.11) 0.91 (0.77–1.07) 0.78 (0.65–0.93) 0.003
Low fat cheese Zero T1 T2 T3
 n/N 533/1,540 85/223 94/258 99/241
 Median 0.0 0.2 0.6 1.2
 Model 1 1.03 (0.93–1.13) 1 1.03 (0.85–1.24) 0.98 (0.81–1.18) 1.10 (0.92–1.31) 0.39
 Model 2 1.03 (0.93–1.13) 1 1.03 (0.85–1.26) 0.99 (0.82–1.19) 1.09 (0.91–1.30) 0.40
 Model 3 1.04 (0.94–1.16) 1 1.03 (0.85–1.25) 0.99 (0.82–1.19) 1.12 (0.93–1.34) 0.30
 Model 4 1.03 (0.93–1.14) 1 1.01 (0.83–1.22) 0.97 (0.80–1.16) 1.09 (0.91–1.30) 0.45
Cream Zero T1 T2 T3
 n/N 341/938 172/421 151/466 147/437
 Median 0.0 0.3 0.4 1.4
 Model 1 0.98 (0.96–1.01) 1 1.01 (0.86–1.20) 0.88 (0.75–1.03) 0.88 (0.74–1.04) 0.09
 Model 2 0.98 (0.96–1.01) 1 1.03 (0.87–1.22) 0.89 (0.76–1.05) 0.87 (0.73–1.03) 0.06
 Model 3 0.98 (0.96–1.01) 1 1.02 (0.86–1.21) 0.89 (0.76–1.05) 0.87 (0.74–1.03) 0.08
 Model 4 0.98 (0.96–1.01) 1 1.03 (0.87–1.21) 0.90 (0.77–1.05) 0.87 (0.73–1.03) 0.06
Ice cream Zero T1 T2 T3
 n/N 263/718 98/280 287/783 163/481
 Median 0.00 0.02 0.05 0.13
 Model 1 0.82 (0.44–1.52) 1 1.04 (0.86–1.27) 0.99 (0.87–1.13) 0.96 (0.82–1.12) 0.49
 Model 2 0.79 (0.43–1.48) 1 1.05 (0.86–1.27) 0.99 (0.87–1.14) 0.95 (0.81–1.12) 0.47
 Model 3 0.79 (0.42–1.48) 1 1.06 (0.87–1.28) 0.99 (0.86–1.13) 0.95 (0.81–1.12) 0.44
 Model 4 0.72 (0.38–1.38) 1 1.04 (0.86–1.26) 0.98 (0.86–1.12) 0.91 (0.78–1.08) 0.22
Open in a new tab

Model 1 included age (continuous), sex, follow-up duration and cohort. Model 2 was additionally adjusted for energy intake (continuous), education (3 categories), smoking (3 categories), physical activity (continuous), alcohol consumption (4 categories) and family history of diabetes (yes/no). Model 3 was additionally adjusted for food groups associated with type 2 diabetes including intakes of fruit, vegetables, tea, coffee, grains (whole and refined), meat (processed and red) and sugar-sweetened beverages (SSB) (continuous). Model 4 was additionally adjusted for BMI (continuous), LDL cholesterol (continuous), systolic and diastolic blood pressure (continuous). Significant associations are indicated in Bold

HS Hoorn Study, T Tertile, Q quartile, RR risk ratio

1Continuous analyses in servings/day: milk, 200 mL; yogurt, 150 mL; cheese, 20 g; cream, 3 g; ice cream, 100 g. Combined total dairy category: liquid dairy products, 200 mL; cheese, 20 g

Interactions were present between the exposures low fat dairy (p = 0.03), low fat fermented dairy (p = 0.01) and low fat cheese (p =  < 0.0001), and enrolment wave. In stratified analysis, low fat fermented dairy and low fat cheese were associated with prediabetes in HS1 (RRservings/day, respectively, 1.10, 95% CI 1.03–1.19, p = 0.01 and 1.33, 95% CI 1.20–1.47, p < 0.001) but not in HS2 (RRservings/day 0.92, 95% CI 0.81–1.05 and 0.92, 95% CI 0.81–1.05) (Supplemental Table 3). Low fat cheese intake was much lower in HS1 as compared to HS2 (10.3% vs 46.2% of low fat fermented dairy). Furthermore, interactions with age were present for low fat dairy (p = 0.004), low fat fermented dairy (p < 0.001), yogurt (p = 0.01), low fat yogurt (p = 0.003), low fat cheese (p = 0.002) and interactions were present with BMI for low fat fermented dairy (p = 0.01) (Supplemental Table 4). Associations between these dairy exposures and prediabetes in participants aged 56 years and over, and in participants with a BMI ≥ 30 were similar as in HS1. Other stratified analysis were not significant.

None of the adjusted associations for substitution of high fat cheese for alternative dairy products were significant (Table 4). We further examined potential confounding of inverse associations between high fat cheese and prediabetes by assessing lifestyle and risk factors according to high fat cheese intake (Supplemental Table 5). In the highest compared to lowest quartile of high fat cheese intake, participants were more often male (53% vs 44%), current smoker (24% vs 17%), used less medication (antihypertensive 10% vs 17%; lipid lowering 2% vs 9%) and had higher LDL cholesterol levels (4.1 ± 1.1 vs 3.5 ± 1.0 mmol/L). Low fat cheese intake was lower and intakes of all other dairy types, energy and processed meat were higher.

Table 4.

Risk ratio's (95% confidence interval) for the substitution of high fat cheese with alternative dairy products and incidence of prediabetes the Hoorn Studies (n = 2262)

High fat cheese RR (95%CI)1
High fat milk, all types 1.06 (0.93–1.21)
Low fat milk, all types 1.06 (0.96–1.16)
High fat yogurt 1.20 (0.99–1.46)
Low fat yogurt 1.09 (0.95–1.26)
Low fat cheese 1.09 (0.98–1.22)
Cream 1.05 (0.98–1.12)
Ice cream 0.82 (0.44–1.54)
Open in a new tab

Substitution models included total servings/day of dairy intake and energy intake (kcal). Models were adjusted for age (continuous), sex, follow-up duration, cohort, education (3 categories), smoking (3 categories), physical activity (continuous), alcohol consumption (4 categories), family history of diabetes (yes/no), intakes of fruit, vegetables, tea, coffee, grains (whole and refined), meat (processed and red) and sugar-sweetened beverages (continuous). Significant associations are indicated in Bold

HS Hoorn Study, RR risk ratio

1Continuous analyses in servings/day: milk, 200 mL; yogurt, 150 mL; cheese, 20 g; cream, 3 g; ice cream, 100 g

Sensitivity analysis

Mutual adjustment for intake of all other dairy types did not result in different associations (Supplementary Table 6). In the sample without CVD at baseline, associations between high fat fermented, total cheese and high fat cheese and prediabetes had similar effect estimates compared to associations in all participants, but these were no longer significant. Using Goldberg cut-offs, we identified 481 ‘under reporters’ (21%) and 62 ‘over reporters’ (3%). Repeating analyses in 1,716 ‘normal reporters’ (76%) resulted in stronger associations for high fat fermented dairy (RRQ4vsQ1 0.79, 95% CI 0.65–0.97, ptrend = 0.04), total cheese (RRQ4vsQ1 0.78, 95% CI 0.64–0.96, ptrend = 0.01, RRservings/day 0.92, 95% CI 0.86–0.99) and high fat cheese (RRQ4vsQ1 0.73, 95% CI 0.60–0.90, ptrend = 0.003, RRservings/day 0.92, 95% CI 0.86–0.99). In ‘normal reporters’, continuous associations were significant for total dairy (RRservings/day 0.95, 95% CI 0.91–0.99, p = 0.03) and total fermented dairy (RRservings/day 0.95, 95% CI 0.90–1.00, p = 0.04) and prediabetes, although associations in quartiles were not. In analysis including participants with prediabetes at baseline, only high fat cheese remained significantly associated with prediabetes (RRQ4vsQ1 0.85, 95% CI 0.73–0.98). Associations between high fat fermented and total cheese and prediabetes were attenuated but remained in the same direction. Sensitivity analyses of substitution of one serving/day of high fat cheese with alternative dairy types resulted in similar associations as in main analysis (Supplemental Table 7).

Discussion

A high intake of high fat fermented dairy, total cheese and high fat cheese were associated with lower risk of prediabetes in this population-based cohort. Associations were driven by high fat cheese intake, as 52% and 83% of, respectively, high fat fermented dairy and total cheese intake consisted of high fat cheese. We found no associations for substitutions of high fat cheese with other dairy products and risk of prediabetes. Total dairy and milk, yogurt, cream and ice cream intake were not associated with prediabetes, irrespective of fat content.

Our observed associations of high fat cheese with prediabetes were consistent with the prospective FHS Offspring Cohort [9]. They reported a non-significant association for the top vs bottom intake of cheese intake (HR 0.86, 95% CI 0.69–1.07), although their cheese intake was considerably lower in the highest intake category compared to ours (median < 1 vs 2.6 servings/day). The cross-sectional Dutch Maastricht study reported an association for higher cheese intake with lower prediabetes risk (OR20g/day 0.88, 95% CI 0.80–0.97) [13]. Similar inverse associations of cheese and 2hPG were also found in the longitudinal Inter99 study (β20g/day − 0.05, 95% CI − 0.01, − 0.001 mmol/L) [11] and in the cross-sectional ELSA-Brasil (β30/day − 0.05, 95% CI − 0.09, − 0.02 mmol/L) [15]. Our findings are in line with a review of three meta-analyses reporting moderate evidence of a prospective association between higher cheese intake and lower T2D risk [8], and the prospective Urban Rural Epidemiology (PURE) study including 131,481 individuals from 21 countries showing a 24% lower risk at > 1 servings/day compared to 0 servings/day (HR 0.76, 95% CI 0.64–0.91, ptrend = 0.001) [31]. Overall, current evidence indicates that higher cheese consumption is associated with lower prediabetes and type 2 diabetes risk.

Our results of no associations between total, low fat and high fat dairy and prediabetes are not in accordance with results from the FHS Offspring Cohort, which reported a lower risk of, respectively, 39%, 32% and 25% in the highest compared to lowest intake category [9]. These associations with prediabetes risk were driven by moderate consumption of low fat, skim milk and whole milk consumption, none of which were significant in our study. Several explanations may underscore these different findings, including a longer follow-up in their study (12 years vs 6.4 years), a higher prediabetes incidence (48.3% vs 35.9%), and a different prediabetes definition (no use of 2hPG and HbA1c, lower cut-off of 5.6 vs 6.0 mmol/L for FPG). Furthermore, they used repeated measurements of dairy intake during follow-up to account for within-person variability, which may have strengthened the associations. Also, in US populations, high dairy consumption is associated with an overall healthier dietary pattern [32], whereas in Europe, dairy consumption is more widespread across a range of populations.

Our results pointed towards effect modification of associations of low fat dairy types and yogurt with prediabetes by enrolment wave, age and BMI. Positive associations for low fat dairy types and prediabetes were shown in HS1, but not in HS2, which could be explained by differences in low fat dairy consumption patterns, such as negligible low fat cheese consumption in HS1. Changes in dairy intake observed between the two enrolment waves correspond to the changes observed from 1987/88 to 2007/10 as assessed in the Dutch National Food Consumption Survey [33]. They showed an increase in intake of dairy, especially of low fat types, skimmed and semi-skimmed yogurt and cheese. Furthermore, differences in characteristics between the enrolment waves could explain effect modification, especially as the HS1 population was somewhat older compared to HS2. Effect modification by enrolment wave may explain positive associations of low fat dairy types and prediabetes present in those with higher age and BMI, as these are not in line with previous studies [9, 34].

We found no associations of yogurt consumption with prediabetes, yet especially higher yogurt consumption has been associated to lower T2D risk in previous high quality research [8]. Significant nonlinear associations of yogurt with prediabetes were found in the FHS Offspring Cohort, with 25% risk reduction observed for 1 to ≤ 3 servings/week compared to no consumption, yet risk increased with higher intakes [9]. Inverse associations between yogurt and prediabetes were also reported by two cross-sectional studies [13, 15], but no associations were found in the much larger Lifelines study [14]. Our neutral observations for yogurt could be due to the inclusion of porridge and custard in this category for HS2, as the HS2 FFQ combined these in a single question. Furthermore, yogurt consumption has been related to healthier diet and lifestyle [13, 35], and residual confounding could explain discrepancies in results across studies.

There are several mechanisms that may explain the observed associations of cheese with prediabetes. Despite an average fat content of 24–35 g/100 g [36] of which 70% SFAs, various RCTs demonstrated less adverse effects of SFAs contained within the cheese matrix compared to SFAs in different matrixes [36–38]. Beneficial associations have been found between ruminant trans fatty acids and insulin resistance and type 2 diabetes [39, 40], with potential mechanisms suggested in animal studies being inhibition of hepatic de novo lipogenesis, activation of PPAR-α and PPAR-γ, improving insulin sensitivity and reducing inflammation [40, 41]. As shown by meta-analysis of 15 RCTs [42], calcium may affect energy balance by increasing faecal fat excretion, due to formation of insoluble Ca-fatty acid soaps and/or formation of hydrophobic aggregations. However, in a meta-analysis of 20 RCTs, calcium supplementation did not reduce body weight or body fat [43]. Fermented foods contain lactic acid bacteria and bioactive molecules, which are beneficial for viability and composition of the gut microbiota and influence gene expression related to glucose and insulin metabolism [41, 44]. Furthermore, vitamin K2 (menaquinones) in dairy is synthesized during fermentation, and cheese is the richest source of vitamin K2 in Western diets (12.7 μg/20 g) [45]. Higher vitamin K2 intake has been related to lower T2D risk in the Dutch EPIC cohort [46]. In animal models of T2D, vitamin K2 supplementation showed dose-dependent reductions of HbA1c and FPG and improved insulin resistance and β-cell function [47, 48]. Vitamin K2 may upregulate carboxylated osteocalcin, resulting in increased serum adiponectin levels, which enhances insulin sensitivity through increased fatty acid oxidation in skeletal muscles and inhibition of hepatic glucose production in the liver [49]. Whether the vitamin K2 induced pathways underline long-term effects of cheese warrants further investigation.

Despite multiple studies pointing to a role of cheese in diabetes prevention, the exact place of cheese in healthy diets is unclear. Current American and European dietary guidelines only advice low fat cheese to limit intake of SFAs and sodium [50], although evidence of more favourable associations of low fat cheese with cardiometabolic outcomes is lacking [51]. The limited evidence available is not sufficient to justify changes to dietary guidelines, and additional well-designed controlled trials are needed.

This study has several strengths, including the assessment of a wide range of dairy subtypes and possibility to disseminate low and high fat types, also for yogurt and cheese. Other strengths include the longitudinal design with 6 years of follow-up and extensive adjustments for confounders. Despite these notable strengths, there are certain limitations that should be mentioned. First, although both FFQs were validated [18, 19], measurement errors in reported dietary intake due to recall bias are unavoidable. We corrected for energy misreporting and found slightly stronger associations in ‘normal reporters’, indicating attenuated effect sizes in main analyses due to energy misreporting. The FFQs used in the two waves were overall comparable, and slight differences in brands and dairy products included largely reflect the changes in dietary patterns between two time periods [33], for example the inclusion of more low fat cheese types in the HS2 cohorts. No compositional changes in dairy products were observed between both NEVO-tables used for calculating nutrient intakes by the FFQ. The main findings and conclusions were similar when stratifying associations by enrolment wave. Second, no repeated measurements of diet were available, and although dietary patterns have shown to be somewhat stable [52, 53], for dairy product intake specifically in comparison to other food groups [53], errors in single dietary measurements may result in bias of associations towards the null. We addressed reverse causality due to dietary changes related to diagnoses of disease by excluding participants with history of diabetes, and excluding participants with prevalent CVD, resulting in similar associations although no longer significant, likely as a result of less power. Lastly, identification of prediabetes cases was less sensitive in HS2 compared to HS1, because no OGTT was done at follow-up and capillary sample HbA1c levels were used, which tend to be higher than venous sample HbA1c levels [54]. Furthermore, reproducibility of FPG and 2hPG is only moderate [55], and participants may revert to normoglycemia during follow-up [5]. We addressed this possible misclassification by including participants with prediabetes at baseline in sensitivity analysis, showing similar significant associations for high fat cheese in quartiles, and other associations remained in similar direction.

In conclusion, higher consumption of high fat cheese was continuously associated with lower risk of prediabetes, suggesting a potential preventive role of cheese in T2D development. Observed associations between higher high fat fermented diary and total cheese consumption and lower prediabetes risk were likely driven by high fat cheese consumption. We found no associations between total dairy, fermented dairy, milk, yogurt, cream and ice cream, regardless of fat content, with prediabetes development. Further prospective and intervention research is needed to elucidate health effects of cheese considering high SFAs and sodium content, and its place in healthy diets.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 126 KB) (125.6KB, docx)

Acknowledgements

We are grateful to the participants, researchers and research assistants of the Hoorn Studies.

Author contribution

IALS and SSS-M designed the research. NdB prepared the datasets for analysis. IALS analysed data and wrote the draft manuscript, supervised by SSS-M. IALS has responsibility for the final content. All authors contributed to the study design and critically reviewed manuscript drafts and approved the final manuscript.

Funding

This work was supported by the Dutch Dairy Association (Nederlandse Zuivel Organisatie) to SSS-M.

Availability of data and material

Data described in the manuscript will be made available upon request pending approval by the authors and approval of the request form, which can be found at https://hoornstudies.com/cohorts-data-request.php.

Code availability

Analytic code (R syntax) will be made available upon request pending approval by the authors.

Declarations

Conflict of interest

SSS-M has received unrestricted grants from the Global Dairy Platform, Dairy Research Institute and Dairy Australia for a meta-analysis on cheese and blood lipids (2012) and a meta-analysis of dairy and mortality (2015). She received the Wiebe Visser International Dairy Nutrition Prize and has received recent research funding (2019) for epidemiological studies on dairy products and cardiometabolic diseases from the Dutch Dairy Association and the Danish Dairy Research Foundation. All other authors declare that they have no conflict of interests.

Ethical approval

The Hoorn Studies were approved by the Medical Ethical Committee of VU University, Amsterdam. All participants gave their written informed consent before the start of the study.

References

  • 1.World Health Organization (WHO) (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation
  • 2.Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R, Committee IDFDA. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843–107843. doi: 10.1016/j.diabres.2019.107843. [DOI] [PubMed] [Google Scholar]
  • 3.Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, Yazdi H, Booker L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305–312. doi: 10.1016/j.diabres.2007.05.004. [DOI] [PubMed] [Google Scholar]
  • 4.Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol. 2011;58(2):140–146. doi: 10.1016/j.jacc.2011.03.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379(9833):2243–2251. doi: 10.1016/S0140-6736(12)60525-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Long GH, Johansson I, Rolandsson O, Wennberg P, Fhärm E, Weinehall L, Griffin SJ, Simmons RK, Norberg M. Healthy behaviours and 10-year incidence of diabetes: a population cohort study. Prev Med. 2015;71:121–127. doi: 10.1016/j.ypmed.2014.12.013. [DOI] [PubMed] [Google Scholar]
  • 7.Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–797. doi: 10.1056/NEJMoa010492. [DOI] [PubMed] [Google Scholar]
  • 8.Alvarez-Bueno C, Cavero-Redondo I, Martinez-Vizcaino V, Sotos-Prieto M, Ruiz JR, Gil A. Effects of milk and dairy product consumption on type 2 diabetes: overview of systematic reviews and meta-analyses. Adv Nutr. 2019;10(suppl_2):S154–S163. doi: 10.1093/advances/nmy107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hruby A, Ma J, Rogers G, Meigs JB, Jacques PF. Associations of dairy intake with incident prediabetes or diabetes in middle-aged adults vary by both dairy type and glycemic status. J Nutr. 2017;147(9):1764–1775. doi: 10.3945/jn.117.253401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fumeron F, Lamri A, Abi Khalil C, Jaziri R, Porchay-Balderelli I, Lantieri O, Vol S, Balkau B, Marre M, Data from the Epidemiological Study on the Insulin Resistance Syndrome Study G Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome: results from a french prospective study, data from the epidemiological study on the insulin resistance syndrome (DESIR) Diabetes Care. 2011;34(4):813–817. doi: 10.2337/dc10-1772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Struijk EA, Heraclides A, Witte DR, Soedamah-Muthu SS, Geleijnse JM, Toft U, Lau CJ. Dairy product intake in relation to glucose regulation indices and risk of type 2 diabetes. Nutr Metab Cardiovasc Dis. 2013;23(9):822–828. doi: 10.1016/j.numecd.2012.05.011. [DOI] [PubMed] [Google Scholar]
  • 12.Snijder MB, van Dam RM, Stehouwer CD, Hiddink GJ, Heine RJ, Dekker JM. A prospective study of dairy consumption in relation to changes in metabolic risk factors: the Hoorn Study. Obesity (Silver Spring) 2008;16(3):706–709. doi: 10.1038/oby.2007.93. [DOI] [PubMed] [Google Scholar]
  • 13.Eussen SJ, van Dongen MC, Wijckmans N, den Biggelaar L, Oude Elferink SJ, Singh-Povel CM, Schram MT, Sep SJ, van der Kallen CJ, Koster A, Schaper N, Henry RM, Stehouwer CD, Dagnelie PC. Consumption of dairy foods in relation to impaired glucose metabolism and type 2 diabetes mellitus: the Maastricht Study. Br J Nutr. 2016;115(8):1453–1461. doi: 10.1017/S0007114516000313. [DOI] [PubMed] [Google Scholar]
  • 14.Brouwer-Brolsma EM, Sluik D, Singh-Povel CM, Feskens EJM. Dairy product consumption is associated with pre-diabetes and newly diagnosed type 2 diabetes in the Lifelines Cohort Study. Br J Nutr. 2018;119(4):442–455. doi: 10.1017/S0007114517003762. [DOI] [PubMed] [Google Scholar]
  • 15.Drehmer M, Pereira MA, Schmidt MI, Del Carmen BMM, Alvim S, Lotufo PA, Duncan BB. Associations of dairy intake with glycemia and insulinemia, independent of obesity, in Brazilian adults: the Brazilian longitudinal study of adult health (ELSA-Brasil) Am J Clin Nutr. 2015;101(4):775–782. doi: 10.3945/ajcn.114.102152. [DOI] [PubMed] [Google Scholar]
  • 16.Rutters F, Nijpels G, Elders P, Stehouwer CDA, van der Heijden AA, Groeneveld L, T’ Hart LM, Dekker JM, Beulens JWJ. Cohort profile: the Hoorn Studies. Int J Epidemiol. 2018;47(2):396–396j. doi: 10.1093/ije/dyx227. [DOI] [PubMed] [Google Scholar]
  • 17.The International Expert Committee International expert committee report on the role of the A1C assay in the diagnosis of Diabetes. Diabetes Care. 2009;32(7):1327–1334. doi: 10.2337/dc09-9033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Grootenhuis PA, Westenbrink S, Sie CM, de Neeling JN, Kok FJ, Bouter LM. A semiquantitative food frequency questionnaire for use in epidemiologic research among the elderly: validation by comparison with dietary history. J Clin Epidemiol. 1995;48(7):859–868. doi: 10.1016/0895-4356(95)00013-t. [DOI] [PubMed] [Google Scholar]
  • 19.Siebelink E, Geelen A, de Vries JHM. Self-reported energy intake by FFQ compared with actual energy intake to maintain body weight in 516 adults. Br J Nutr. 2011;106(2):274–281. doi: 10.1017/S0007114511000067. [DOI] [PubMed] [Google Scholar]
  • 20.Streppel MT, de Vries JH, Meijboom S, Beekman M, de Craen AJ, Slagboom PE, Feskens EJ. Relative validity of the food frequency questionnaire used to assess dietary intake in the Leiden Longevity Study. Nutr J. 2013;12:75. doi: 10.1186/1475-2891-12-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lakshmy R, Gupta R. Measurement of glycated hemoglobin A1c from dried blood by turbidimetric immunoassay. J Diabetes Sci Technol. 2009;3(5):1203–1206. doi: 10.1177/193229680900300527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56(12):1163–1169. doi: 10.1016/s0895-4356(03)00220-8. [DOI] [PubMed] [Google Scholar]
  • 23.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. doi: 10.1093/clinchem/18.6.499. [DOI] [PubMed] [Google Scholar]
  • 24.Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. CMAJ. 2012;184(8):895–899. doi: 10.1503/cmaj.101715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Soedamah-Muthu SS, de Goede J. Dairy consumption and cardiometabolic diseases: systematic review and updated meta-analyses of prospective cohort studies. Curr Nutr Rep. 2018;7(4):171–182. doi: 10.1007/s13668-018-0253-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Health Council of the Netherlands. Dutch dietary guidelines 2015. The Hague: Health Council of the Netherlands, 2015; publication no. 2015/24E
  • 27.Schwingshackl L, Hoffmann G, Lampousi A-M, Knüppel S, Iqbal K, Schwedhelm C, Bechthold A, Schlesinger S, Boeing H. Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Eur J Epidemiol. 2017;32(5):363–375. doi: 10.1007/s10654-017-0246-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Laursen ASD, Dahm CC, Johnsen SP, Tjonneland A, Overvad K, Jakobsen MU. Substitutions of dairy product intake and risk of stroke: a Danish cohort study. Eur J Epidemiol. 2018;33(2):201–212. doi: 10.1007/s10654-017-0271-x. [DOI] [PubMed] [Google Scholar]
  • 29.Black AE. Critical evaluation of energy intake using the Goldberg cut-off for energy intake:basal metabolic rate. A practical guide to its calculation, use and limitations. Int J Obes Relat Metab Disord. 2000;24(9):1119–1130. doi: 10.1038/sj.ijo.0801376. [DOI] [PubMed] [Google Scholar]
  • 30.Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr. 1985;39(Suppl 1):5–41. [PubMed] [Google Scholar]
  • 31.Bhavadharini B, Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, Iqbal R, Gupta R, Lear S, Wentzel-Viljoen E, Avezum A, Lopez-Jaramillo P, Mony P, Varma RP, Kumar R, Chifamba J, Alhabib KF, Mohammadifard N, Oguz A, Lanas F, Rozanska D, Bengtsson Bostrom K, Yusoff K, Tsolkile LP, Dans A, Yusufali A, Orlandini A, Poirier P, Khatib R, Hu B, Wei L, Yin L, Deeraili A, Yeates K, Yusuf R, Ismail N, Mozaffarian D, Teo K, Anand SS, Yusuf S. Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries. BMJ Open Diabetes Res Care. 2020;8(1):e000826. doi: 10.1136/bmjdrc-2019-000826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015 – 2020 Dietary Guidelines for Americans. 8th Edition (2015). Available at https://health.gov/our-work/food-nutrition/previous-dietary-guidelines/2015
  • 33.Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2013) Veranderingen in het aanbod van voedingsmiddelen en de voedselconsumptie
  • 34.Gijsbers L, Ding EL, Malik VS, de Goede J, Geleijnse JM, Soedamah-Muthu SS. Consumption of dairy foods and diabetes incidence: a dose-response meta-analysis of observational studies. Am J Clin Nutr. 2016;103(4):1111–1124. doi: 10.3945/ajcn.115.123216. [DOI] [PubMed] [Google Scholar]
  • 35.Tremblay A, Panahi S. Yogurt consumption as a signature of a healthy diet and lifestyle. J Nutr. 2017;147(7):1476s–1480s. doi: 10.3945/jn.116.245522. [DOI] [PubMed] [Google Scholar]
  • 36.Thorning TK, Bertram HC, Bonjour JP, de Groot L, Dupont D, Feeney E, Ipsen R, Lecerf JM, Mackie A, McKinley MC, Michalski MC, Remond D, Riserus U, Soedamah-Muthu SS, Tholstrup T, Weaver C, Astrup A, Givens I. Whole dairy matrix or single nutrients in assessment of health effects: current evidence and knowledge gaps. Am J Clin Nutr. 2017;105(5):1033–1045. doi: 10.3945/ajcn.116.151548. [DOI] [PubMed] [Google Scholar]
  • 37.Feeney EL, Barron R, Dible V, Hamilton Z, Power Y, Tanner L, Flynn C, Bouchier P, Beresford T, Noronha N, Gibney ER. Dairy matrix effects: response to consumption of dairy fat differs when eaten within the cheese matrix-a randomized controlled trial. Am J Clin Nutr. 2018;108(4):667–674. doi: 10.1093/ajcn/nqy146. [DOI] [PubMed] [Google Scholar]
  • 38.de Goede J, Geleijnse JM, Ding EL, Soedamah-Muthu SS. Effect of cheese consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2015;73(5):259–275. doi: 10.1093/nutrit/nuu060. [DOI] [PubMed] [Google Scholar]
  • 39.Imamura F, Fretts A, Marklund M, Ardisson Korat AV, Yang WS, Lankinen M, Qureshi W, Helmer C, Chen TA, Wong K, Bassett JK, Murphy R, Tintle N, Yu CI, Brouwer IA, Chien KL, Frazier-Wood AC, Del Gobbo LC, Djoussé L, Geleijnse JM, Giles GG, de Goede J, Gudnason V, Harris WS, Hodge A, Hu F, Koulman A, Laakso M, Lind L, Lin HJ, McKnight B, Rajaobelina K, Risérus U, Robinson JG, Samieri C, Siscovick DS, Soedamah-Muthu SS, Sotoodehnia N, Sun Q, Tsai MY, Uusitupa M, Wagenknecht LE, Wareham NJ, Wu JH, Micha R, Forouhi NG, Lemaitre RN, Mozaffarian D. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. PLoS Med. 2018;15(10):e1002670. doi: 10.1371/journal.pmed.1002670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Tremblay BL, Rudkowska I. Nutrigenomic point of view on effects and mechanisms of action of ruminant trans fatty acids on insulin resistance and type 2 diabetes. Nutr Rev. 2017;75(3):214–223. doi: 10.1093/nutrit/nuw066. [DOI] [PubMed] [Google Scholar]
  • 41.Mozaffarian D, Wu JHY. Flavonoids, dairy foods, and cardiovascular and metabolic health: a review of emerging biologic pathways. Circ Res. 2018;122(2):369–384. doi: 10.1161/circresaha.117.309008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Christensen R, Lorenzen JK, Svith CR, Bartels EM, Melanson EL, Saris WH, Tremblay A, Astrup A. Effect of calcium from dairy and dietary supplements on faecal fat excretion: a meta-analysis of randomized controlled trials. Obes Rev. 2009;10(4):475–486. doi: 10.1111/j.1467-789X.2009.00599.x. [DOI] [PubMed] [Google Scholar]
  • 43.Booth AO, Huggins CE, Wattanapenpaiboon N, Nowson CA. Effect of increasing dietary calcium through supplements and dairy food on body weight and body composition: a meta-analysis of randomised controlled trials. Br J Nutr. 2015;114(7):1013–1025. doi: 10.1017/S0007114515001518. [DOI] [PubMed] [Google Scholar]
  • 44.Fernandez MA, Marette A. Novel perspectives on fermented milks and cardiometabolic health with a focus on type 2 diabetes. Nutr Rev. 2018;76(Suppl 1):16–28. doi: 10.1093/nutrit/nuy060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 2000;30(6):298–307. doi: 10.1159/000054147. [DOI] [PubMed] [Google Scholar]
  • 46.Beulens JW, Grobbee DE, Sluijs I, Spijkerman AM, van der Schouw YT. Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care. 2010;33(8):1699–1705. doi: 10.2337/dc09-2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hussein AG, Mohamed RH, Shalaby SM, Abd El Motteleb DM. Vitamin K2 alleviates type 2 diabetes in rats by induction of osteocalcin gene expression. Nutrition. 2018;47:33–38. doi: 10.1016/j.nut.2017.09.016. [DOI] [PubMed] [Google Scholar]
  • 48.Iwamoto J, Seki A, Sato Y, Matsumoto H, Takeda T, Yeh JK. Vitamin K2 prevents hyperglycemia and cancellous osteopenia in rats with streptozotocin-induced type 1 diabetes. Calcif Tissue Int. 2011;88(2):162–168. doi: 10.1007/s00223-010-9441-5. [DOI] [PubMed] [Google Scholar]
  • 49.Li Y, Chen JP, Duan L, Li S. Effect of vitamin K2 on type 2 diabetes mellitus: a review. Diabetes Res Clin Pract. 2018;136:39–51. doi: 10.1016/j.diabres.2017.11.020. [DOI] [PubMed] [Google Scholar]
  • 50.Soedamah-Muthu S, Guo J. Dairy consumption and cardiometabolic diseases: evidence from prospective studies. In: Givens DI, editor. Milk and dairy foods: their functionality in human health and disease. Cambridge: Academic Press; 2020. pp. 1–28. [Google Scholar]
  • 51.Drouin-Chartier JP, Brassard D, Tessier-Grenier M, Cote JA, Labonte ME, Desroches S, Couture P, Lamarche B. Systematic review of the association between dairy product consumption and risk of cardiovascular-related clinical outcomes. Adv Nutr. 2016;7(6):1026–1040. doi: 10.3945/an.115.011403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Jankovic N, Steppel MT, Kampman E, de Groot LC, Boshuizen HC, Soedamah-Muthu SS, Kromhout D, Feskens EJ. Stability of dietary patterns assessed with reduced rank regression; the Zutphen elderly study. Nutr J. 2014;13:30. doi: 10.1186/1475-2891-13-30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Nagel G, Zoller D, Ruf T, Rohrmann S, Linseisen J. Long-term reproducibility of a food-frequency questionnaire and dietary changes in the European prospective investigation into cancer and nutrition (EPIC)-Heidelberg cohort. Br J Nutr. 2007;98(1):194–200. doi: 10.1017/s0007114507691636. [DOI] [PubMed] [Google Scholar]
  • 54.Anjali GFS, Kumar RS, Seshadri MS. Accuracy of filter paper method for measuring glycated hemoglobin. J Assoc Physicians India. 2007;55:115–119. [PubMed] [Google Scholar]
  • 55.Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55(1):65–85. doi: 10.1016/s0168-8227(01)00365-5. [DOI] [PubMed] [Google Scholar]
  • 56.Looman M, Feskens EJ, de Rijk M, Meijboom S, Biesbroek S, Temme EH, de Vries J, Geelen A. Development and evaluation of the Dutch healthy diet index 2015. Public Health Nutr. 2017;20(13):2289–2299. doi: 10.1017/s136898001700091x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary file1 (DOCX 126 KB) (125.6KB, docx)

Data Availability Statement

Data described in the manuscript will be made available upon request pending approval by the authors and approval of the request form, which can be found at https://hoornstudies.com/cohorts-data-request.php.

Analytic code (R syntax) will be made available upon request pending approval by the authors.

Articles from European Journal of Nutrition are provided here courtesy of Springer

RESOURCES